Thirteen years from founding, Epizyme scores first FDA approval
Epizyme’s foundational epigenetics hypothesis pays off with approval of first-in-class drug for epithelioid sarcoma
Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang its hat and foundational hypothesis. On Thursday, its Tazverik tazemetostat became the first approved therapy to treat epithelioid sarcoma.
FDA granted accelerated approval to the